| Autor: |
Overbosch FW; Department of Infectious Diseases, Public Health Service (GGD), Amsterdam, the Netherlands., Schinkel J; Department of Medical Microbiology, Laboratory of Clinical Virology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, the Netherlands., Matser A; Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AIII), Amsterdam UMC, location Academic Medical Center, Amsterdam, the Netherlands.; Department of Infectious Diseases Research and Prevention, Public Health Service (GGD), Amsterdam, the Netherlands., Koen G; Department of Medical Microbiology, Laboratory of Clinical Virology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, the Netherlands., Prange I; Department of Infectious Diseases, Public Health Service (GGD), Amsterdam, the Netherlands., Prins M; Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AIII), Amsterdam UMC, location Academic Medical Center, Amsterdam, the Netherlands.; Department of Infectious Diseases Research and Prevention, Public Health Service (GGD), Amsterdam, the Netherlands., Sonder GJ; Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AIII), Amsterdam UMC, location Academic Medical Center, Amsterdam, the Netherlands.; Department of Infectious Diseases, Public Health Service (GGD), Amsterdam, the Netherlands. |
| Abstrakt: |
BackgroundSuriname, a country endemic for dengue virus (DENV), is a popular destination for Dutch travellers visiting friends and relatives and tourist travellers. Chikungunya and Zika virus (CHIKV, ZIKV) were introduced in 2014 and 2015, respectively. Data on infection risks among travellers are limited.AimWe aimed to prospectively study incidence rate (IR) and determinants for DENV, ZIKV and CHIKV infection in adult travellers to Suriname from 2014 through 2017.MethodsParticipants kept a travel diary and were tested for anti-DENV, anti-ZIKV and anti-CHIKV IgG antibodies (Euroimmun). Selected samples were subjected to an in-house DENV and ZIKV PRNT50. The IR (infections/1,000 person-months of travel) and IR ratio and determinants for infection were calculated.ResultsTravel-acquired infections were found in 21 of 481 participants: 18 DENV, four ZIKV and two CHIKV, yielding an IR DENV of 47.0 (95% CI: 29.6-74.6), IR ZIKV of 11.6 (95% CI: 4.4-31.0) and IR CHIKV of 5.6 (95% CI: 1.4-22.2)/1,000 person-months. In nine DENV and three ZIKV infected participants, infections were PRNT50-confirmed, yielding a lower IR DENV of 23.3 (95% CI: 12.1-44.8) and an IR ZIKV of 8.4 (95% CI: 2.7-26.1) per 1,000 person-months. Tourist travel was associated with DENV infection. ZIKV and CHIKV infections occurred soon after their reported introductions.ConclusionsDespite an overestimation of serologically confirmed infections, Dutch travellers to Suriname, especially tourists, are at substantial risk of DENV infection. As expected, the risk of contracting ZIKV and CHIKV was highest during outbreaks. Cross-reaction and potential cross-protection of anti-DENV and -ZIKV antibodies should be further explored. |
